Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Liabilities and Shareholders Equity (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $3.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 66.12% to $3.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $19.0 million, a 5.01% decrease, with the full-year FY2024 number at $5.6 million, up 106.69% from a year prior.
  • Liabilities and Shareholders Equity was $3.2 million for Q3 2025 at Ensysce Biosciences, down from $5.6 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $16.4 million in Q4 2021 to a low of $2.7 million in Q4 2023.
  • A 5-year average of $7.1 million and a median of $5.9 million in 2022 define the central range for Liabilities and Shareholders Equity.
  • Biggest YoY gain for Liabilities and Shareholders Equity was 4566.58% in 2021; the steepest drop was 78.93% in 2021.
  • Ensysce Biosciences' Liabilities and Shareholders Equity stood at $16.4 million in 2021, then tumbled by 64.15% to $5.9 million in 2022, then crashed by 53.98% to $2.7 million in 2023, then skyrocketed by 106.69% to $5.6 million in 2024, then crashed by 43.2% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Liabilities and Shareholders Equity are $3.2 million (Q3 2025), $5.6 million (Q2 2025), and $4.6 million (Q1 2025).